Mitochondrial Reactive Oxygen Species and Redox System (Mitochondrial Redox/ROS System)

The cancer cell mitochondrial redox/ROS system is a complex network of enzymes and molecules that maintain oxidative homeostasis within the mitochondria of malignant cells. Cancer cells typically exhibit elevated levels of reactive oxygen species (ROS) compared to normal cells, driven by oncogenic signaling and metabolic reprogramming (Gorrini et al., 2013, Nature Reviews Drug Discovery). To survive this oxidative stress, cancer cells upregulate antioxidant defense systems, such as the glutathione (GSH) and thioredoxin (Trx) pathways, making these systems attractive therapeutic targets (Trachootham et al., 2009, Nature Reviews Drug Discovery). Pharmacological strategies often involve the use of pro-oxidants to push ROS levels beyond a lethal threshold or the inhibition of specific antioxidant enzymes to induce mitochondria-mediated apoptosis (Fulda et al., 2010, Nature Reviews Drug Discovery). However, the lack of specificity for cancer mitochondria over healthy ones and the potential for cancer cells to develop resistance through compensatory mechanisms remain significant hurdles in clinical application (Sabharwal & Schumacker, 2014, Nature Reviews Cancer). This system's role in regulating cell death pathways makes it a focal point for developing next-generation precision oncology treatments.

Other names

Mitochondrial oxidative stress systemMitochondrial redox homeostasisCancer mitochondrial redox signalingMitochondrial antioxidant system

Induction of oxidative stress through ROS generation or inhibition of antioxidant defense mechanisms (e.g., thioredoxin reductase or glutathione systems) to trigger mitochondrial apoptosis.